FDA medical journals advisory panel proposed by AMA in comments on reprint guidance.

Executive Summary

FDA MEDICAL JOURNAL ADVISORY PANEL PROPOSED BY AMA in comments on FDA's December guidance to industry on dissemination of journal reprints. The American Medical Association suggests in Jan. 17 comments that FDA should allow dissemination of articles on off-label uses. As one restriction on such dissemination, AMA suggests, FDA should require that a "journal is recognized to be of national scope and reputation, as defined by an advisory panel to the FDA" with representation from national medical societies.